Tonix Pharmaceuticals Holding Corp (LTS:0A4T)
$ 134.6 0 (0%) Market Cap: 17.80 Mil Enterprise Value: 12.04 Mil PE Ratio: 0 PB Ratio: 0.40 GF Score: 31/100

Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference Transcript

Jan 14, 2021 / 02:15PM GMT
Release Date Price: $189.6 (-2.92%)
Peter Vozzo
Westwicke ICR - Moderator

Good morning, everyone. Thank you for joining us today for the ICR conference. I'm Peter Vozzo, Managing Director at Westwicke ICR. And it's my pleasure to introduce Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals. Tonix is a clinical-stage biopharmaceutical company focused on central nervous system and immunology product candidates.

Seth is going to provide an overview of the company, which we will then follow with the Q&A session. (Conference Instructions)

With that, I'll turn it over to Seth.

Seth Lederman
Tonix Pharmaceuticals Holding Corp. - Co-Founder, CEO & Chairman

Thank you, Peter, and thanks to the ICR organizers. It's a pleasure to be here. It's a very exciting time for Tonix. It's the best time in Tonix history. We have a lot of interesting news. And for those who haven't been following this story, we just announced a positive Phase 3 study in fibromyalgia in December.

So we are mid-Phase 3 in that program. We're recruiting in a second

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot